Corrigendum: Longitudinal “Real-World” Outcomes of Pirfenidone in Idiopathic Pulmonary Fibrosis in Greece

Bibliographic Details
Published in:	Frontiers in Medicine
Main Authors:	Argyrios Tzouvelekis, Theodoros Karampitsakos, Paschalis Ntolios, Vasilios Tzilas, Evangelos Bouros, Evangelos Markozannes, Ioanna Malliou, Aris Anagnostopoulos, Andreas Granitsas, Paschalis Steiropoulos, Katerina Dimakou, Serafeim Chrysikos, Nikolaos Koulouris, Demosthenes Bouros
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2018-01-01
Subjects:	pirfenidone safety efficacy idiopathic pulmonary fibrosis treatment
Online Access:	http://journal.frontiersin.org/article/10.3389/fmed.2017.00257/full

Similar Items

Longitudinal “Real-World” Outcomes of Pirfenidone in Idiopathic Pulmonary Fibrosis in Greece
by: Argyrios Tzouvelekis, et al.
Published: (2017-11-01)

Metabolic Disorders in Chronic Lung Diseases
by: Ourania Papaioannou, et al.
Published: (2018-01-01)

The Role of Microbiome and Virome in Idiopathic Pulmonary Fibrosis
by: Paschalis Ntolios, et al.
Published: (2021-04-01)

Effect and Safety of Mycophenolate Mofetil in Idiopathic Pulmonary Fibrosis
by: Argyris Tzouvelekis, et al.
Published: (2011-01-01)

Presenting clinical and imaging features of patients with clinically amyopathic interstitial lung disease associated with myositis-specific autoantibodies
by: Vasilios Tzilas, et al.
Published: (2024-04-01)

Impact of Depression on Patients With Idiopathic Pulmonary Fibrosis
by: Argyris Tzouvelekis, et al.
Published: (2020-02-01)

The Role of Hydroxychloroquine in Coronavirus Disease 2019. A Versatile Tool at the Service of Humanity
by: Argyris Tzouvelekis, et al.
Published: (2020-04-01)

Effect and Safety of Mycophenolate Mofetil or Sodium in Systemic Sclerosis-Associated Interstitial Lung Disease: A Meta-Analysis
by: Argyris Tzouvelekis, et al.
Published: (2012-01-01)

Lung Cancer and Interstitial Lung Diseases: A Systematic Review
by: Kostas Archontogeorgis, et al.
Published: (2012-01-01)

Biologic Treatments in Interstitial Lung Diseases
by: Theodoros Karampitsakos, et al.
Published: (2019-03-01)

Reactivation pulmonary tuberculosis in two patients treated with pirfenidone
by: Mohammad Khan, et al.
Published: (2017-01-01)

An Open-Label, Phase II Study of the Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (PIPF-002)
by: Mark H. Gotfried, et al.
Published: (2018-06-01)

Effect of pirfenidone on tendon healing
by: Yasemin Aydinli, et al.
Published: (2023-01-01)

Inhibition of Ureteral Stricture by Pirfenidone-Loaded Nanoparticle-Coated Ureteral Stents with Slow-Release Pirfenidone
by: Jiang Z, et al.
Published: (2022-12-01)

Pirfenidone in Skin Fibrosis and Scarring: From Bench Insights to Clinical Data
by: Kelson Knighton, et al.
Published: (2025-08-01)

Rituximab and Pirfenidone in the Treatment of Steroid‐Refractory Bleomycin Lung Injury
by: Aasir M. Suliman, et al.
Published: (2025-07-01)

Can Pirfenidone and Nintedanib Be Alternative Treatment Options for Radiation Pneumonitis?
by: Hikmet COBAN, et al.
Published: (2025-06-01)

Role of pirfenidone in the management of pulmonary fibrosis
by: Meyer KC, et al.
Published: (2017-04-01)

Pirfenidone and Nintedanib in idiopathic pulmonary fibrosis: Real-life experience in an Italian referral centre
by: E. Bargagli, et al.
Published: (2019-05-01)

The pulmoprotective effects of pirfenidone against paraquat-induced pulmonary toxicity: a systematic review
by: Sajjad Sadeghi, et al.
Published: (2025-06-01)

Preparation of Novel Pirfenidone Microspheres for Lung-Targeted Delivery: In vitro and in vivo Study [Retraction]
by: Li D, et al.
Published: (2022-11-01)

Refractory Spontaneous Pneumothorax in Interstitial Lung Disease Under Pirfenidone Treatment
by: Jaejun Jeong, et al.
Published: (2025-10-01)

Inhibition of urethral stricture by a catheter loaded with nanoparticle/ pirfenidone complexes
by: Wei Meng, et al.
Published: (2023-10-01)

Metformin enhanced the effect of pirfenidone on pulmonary fibrosis in mice
by: Nana Liu, et al.
Published: (2024-01-01)

Idiopathic Pulmonary Hemosiderosis in Adults: A Case Report and Review of the Literature
by: Argyris Tzouvelekis, et al.
Published: (2012-01-01)

Efficacy and safety of nintedanib in a Greek multicentre idiopathic pulmonary fibrosis registry: a retrospective, observational, cohort study
by: Katerina Antoniou, et al.
Published: (2020-01-01)

Pirfenidone use in fibrotic diseases: What do we know so far?
by: Aldo Torre, et al.
Published: (2024-07-01)

Pirfenidone treatment in idiopathic pulmonary fibrosis: nationwide Danish results
by: Goran Nadir Salih, et al.
Published: (2016-09-01)

Topical Pirfenidone-Loaded Liposomes Ophthalmic Formulation Reduces Haze Development after Corneal Alkali Burn in Mice
by: Carlos Daniel Diaz-Palomera, et al.
Published: (2022-01-01)

Complete Blood Cell Count Parameters Predict Mortality in Patients with Hypersensitivity Pneumonitis
by: Matthaios Katsaras, et al.
Published: (2025-04-01)

Pirfenidone combined with UC-MSCs reversed bleomycin-induced pulmonary fibrosis
by: Jingran Xu, et al.
Published: (2025-08-01)

Effects of Pirfenidone on Idiopathic Pulmonary Fibrosis Progression and Safety: Results of Multicenter Prospective Observational Study
by: Sergey Avdeev, et al.
Published: (2023-02-01)

Acneiform drug eruption from pirfenidone
by: Jordyn Puccio, BS, et al.
Published: (2025-07-01)

Pirfenidone Protects from UVB-Induced Photodamage in Hairless Mice
by: Yocasta Martinez-Alvarado, et al.
Published: (2023-03-01)

Combination of Niclosamide and Pirfenidone Alleviates Pulmonary Fibrosis by Inhibiting Oxidative Stress and MAPK/Nf-κB and STATs Regulated Genes
by: Hanaa Wanas, et al.
Published: (2023-05-01)

Rural treatment of COVID-19 patients with pirfenidone, nitazoxanide and colchicine. Case series
by: Brandon Iturbe Esquivel, et al.
Published: (2022-06-01)

Bibliometric analysis of the pirfenidone and nintedanib in interstitial lung diseases
by: Jia Liu, et al.
Published: (2024-04-01)

Serum biomarkers in interstitial lung diseases
by: Anevlavis Stavros, et al.
Published: (2005-07-01)

The Management of Patients With Idiopathic Pulmonary Fibrosis
by: Paolo Spagnolo, et al.
Published: (2018-07-01)

Comparison of the Effects of Nintedanib and Pirfenidone on Pulmonary Function Test Parameters and Radiological Findings in Patients with Idiopathic Pulmonary Fibrosis: A Real-Life Study
by: Olcay Aycicek, et al.
Published: (2025-02-01)